Evaluation of adverse events of oral antihyperglycaemic monotherapy experienced by a geriatric population in a real-world setting: A retrospective cohort analysis

Drugs and Aging

Volumn 25, Issue 7, 2008, Pages 611-622

  Asche, Carl V ^a   McAdam Marx, Carrie ^a   Shane McWhorter, Laura ^a   Sheng, Xiaoming ^b   Plauschinat, Craig A ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antihyperglycaemics, adverse reactions; Diabetes mellitus, treatment; Elderly; Metformin, adverse reactions; Sulfonylureas, adverse reactions; Thiazolidinediones, adverse reactions

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; LAXATIVE; METFORMIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; AGED; ARTICLE; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DYSPEPSIA; EDEMA; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; GERIATRIC CARE; HEADACHE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; VOMITING; WEIGHT GAIN;

ADMINISTRATION, ORAL; AGE FACTORS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; METFORMIN; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 46349089552     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825070-00006     Document Type: Article

References (43)

1. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2006; 29: 1263-8
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 1997. Diabetes Care 1998; 21: 296-309
3. McKinlay J, Marceau L. US public health and the 21st century: diabetes mellitus. Lancet 2000; 356: 757-61
4. Smith NL, Heckbert SR, Bittner VA, et al. Antidiabetic treatment trends in a cohort of elderly people with diabetes: the cardiovascular health study, 1989-1997. Diabetes Care 1999; 22: 736-42
5. Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population: the Rotterdam Study. Diabetes Care 1997; 20: 792-5
6. Gregg EW, Engelgau MM, Narayan V. Complications of diabetes in elderly people. BMJ 2002; 325: 916-7
7. Strachan MWJ, Frier BM, Deary IJ. Type 2 diabetes and cognitive impairment. Diabet Med 2003; 20: 1-2
8. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993; 328: 1676-85
9. UKPDS Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
10. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci 2001; 56: M5-13
11. Ryan CM, Freed MI, Rood JA, et al. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006; 29: 345-51
12. Morisaki N, Watanabe S, Kobayashi J, et al. Diabetic control and progression of retinopathy in elderly patients: five-year follow-up study. J Am Geriatr Soc 1994; 42: 142-5
13. Herman WH. Clinical evidence: glycaemic control in diabetes. BMJ 1999; 319: 104-6
14. Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51: S265-80
15. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20
16. Skaer TL, Sclar DA, Robison LM. Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation? Diabetes Educ 2006; 32: 940-53
17. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-72
18. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72
19. Ben-Ami H, Nagachandran P, Mendelson A, et al. Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 1999; 159: 281-4
20. Seltzer HS. Drug-induced hypoglycaemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163-83
21. EncoderPro.com. Ingenix, 2008 [online]. Available from URL: http://www.encoderpro.com [Accessed 2006 Nov 15]
22. Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24: 308-15
23. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074-95
24. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-8
25. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007; 357: 28-38
26. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab 2007; 9: 96-102
27. Charbonnel BH, Matthews DR, Schernthaner G, et al. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005; 22: 399-405
28. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage®; XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabet Obes Metab 2005; 7: 28-39
29. Garber AJ, Donovan Jr DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3598-604
30. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491-7
31. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabet Obes Metab 2002; 4: 201-8
32. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006 Jan 25; (1): CD002967
33. Belcher G, Lambert C, Edwards G, et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabet Res Clin Pract 2005; 70: 53-62
34. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-42
35. Weitgasser R, Lechleitner M, Luger A, et al. Effects of glimepiride on HbA1c and body weight in type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res Clin Pract 2003; 61: 13-9
36. Inoue K, Ikegami H, Fujisawa T, et al. Less frequent body weight gain in elderly type 2 diabetic patients treated with glimepiride. Geriatr Gerontol Int 2003; 3: 56-9
37. Schade D, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998; 38: 636-41
38. Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Quartet Study Group. J Clin Endocrinol Metab 2004; 89: 6068-76
39. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-21
40. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43
41. Massi-Benedetti M. Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience. Clin Ther 2003; 25: 799-816
42. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003; 9: 406-16
43. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-ride insulin dependent diabetes followed for three years. BMJ 1995; 310: 83-8